NasdaqGS · Biotechnology

Upstream Bio (UPB)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+380.6%

$33.50 average target

$6.97+0.12 (+1.8%)Latest market snapshot · Yahoo Finance

Market cap$381.8M

Cash$261.3M

Quarterly burn$47.9M

Pipeline assets3

Short float10.2%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 380.6% upsideTargets are estimates—not guarantees—and can change after company updates.

$33.50Average target

Wall Street consensus

BuyBased on 8 analyst opinions

9ratings

Buy 7Hold 2Sell 0

Price-target range

$33.50

+380.6%

Low $9.00High $75.00

CurrentAverage

Bear case$9.00+29.1%

Base case$33.50+380.6%

Bull case$75.00+976.0%

Analyst coverage8published opinions

Bullish share78%buy recommendations

Target spread$66low-to-high dispersion

Consensus score1.61.0 is strongest

Recommendation mix

Current rating breakdown

9 tracked ratings

Company profile

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.